Table 2.
Risk of bias assessment for included randomized controlled clinical trials
| Study | Random sequence generatin (Selection bias) | Allocation concealment (Selection bias) | Blinding of participants and personnel (Performance bias) | Blinding of outcome assessment (Detection bias) | Incomplete outcome data (Attrition bias) | Selective reporting (Reporting bias) | Overall quality |
|---|---|---|---|---|---|---|---|
| Lu et al. [32] | Unclear | Unclear | Low | Unclear | Unclear | Low | Fair |
| Kanellos et al. [43] | Low | Low | Low | Low | Unclear | Low | Good |
| Saldanha et al. [36] | Low | Low | Low | Low | Low | Low | Good |
| Taghizadeh et al. [42] | Low | Low | Low | Unclear | Low | Low | Good |
| Torres et al. [118] | Unclear | Unclear | Unclear | Unclear | low | Low | Fair |
| Macedo et al. [45] | Unclear | Unclear | Low | Unclear | Unclear | Low | Fair |
| Zunino et al. [38] | Unclear | Unclear | Low | Unclear | Low | Low | Good |
| Evans et al. | Low | Unclear | Low | Unclear | Low | Low | Good |
| Amoutzopoulos et al. | Unclear | Unclear | Unclear | Unclear | Low | Low | Fair |
| Noguer et al. [117] | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Weak |
| Pourghassem et al. [44] | Unclear | Unclear | Unclear | Unclear | Low | Low | Fair |
| Mellen et al. [119] | Unclear | Unclear | Low | Unclear | Low | Low | Good |
| Estruch et al .[115] | Low | Unclear | Unclear | Unclear | Low | Low | Good |
| Lafay et al. [116] | Unclear | Unclear | Low | Unclear | Unclear | Low | Good |
| Hollis et al. [37] | Unclear | Unclear | Unclear | Unclear | Low | Low | Fair |
| Rankin et al. [39] | Unclear | Unclear | Unclear | Unclear | Low | Low | Fair |
| Avellone et al. [114] | Unclear | Unclear | Unclear | Unclear | Unclear | Low | Weak |